Monday, 3 July 2017

Autologous Stem Cell and Non-Stem Cell Based Therapies Market - Worldwide Industry Analysis and Forecast 2015 - 2023

Autologous Stem Cell and Non-Stem Cell Based Therapies Market: Brief Account 

The report is a thorough analysis of the autologous stem cell and non-stem cell based therapies market. Comprising an in-depth analysis of the various factors boosting and inhibiting the growth of the market, this report is a key to making profitable decisions by investing in the correct segment and sub-segment, which is anticipated to make the most progress in the future.  

In autologous stem cell and non-stem cell based therapies, an individual’s cell is cultured and then re-introduced to the donor’s body. Used for the treatment of various bone marrow diseases, autologous stem cell and non-stem cell based therapies allows patients to have normal bone marrow, which gets destroyed in chemotherapy. The various diseases that can be treated with the help of autologous stem cell and non-stem cell based therapies include: multiple myeloma, aplastic anemia, non-Hodgkin’s lymphoma, Parkinson’s disease, Hodgkin’s lymphoma, thalassemia, and diabetes. Thus, the demand for this therapy is projected to rise over the coming years. 


Autologous Stem Cell and Non-Stem Cell Based Therapies Market: Trends and Opportunities 

One of the key drivers for this market is the rise in the prevalence of cancer and diabetes among people across all age groups. Moreover, the growing geriatric population is another factor, which is likely to create a heightened demand for autologous stem cell and non-stem cell based therapies. Favorable reimbursement policies across several nations are also aiding the growth of this market. 

Players in the market are striving to achieve therapies that are not only safe and effective but also affordable and easy to use. Players are also investing in extensive research and development so as to speed up the treatment process of autologous stem cell and non-stem cell based therapies. While currently this treatment is quite expensive, government bodies are expected to take up initiatives and make the therapy affordable in the years to come. This is expected to drive the market in the future. 

On the other hand, challenges faced by the global autologous stem cell and non-stem cell based therapies market include risks and complications associated with the therapy, such as diarrhea, hair loss,  nausea, severe infections, vomiting, heart complications, and infertility. 

Autologous Stem Cell and Non-Stem Cell Based Therapies Market: Geographical Analysis 

By geography, North America, trailed by Europe is leading in the autologous stem cell and non-stem cell based therapies market, on account of the minimization of risks associated with the therapy. Also, these therapies are highly in demand owing to their ability to treat a large number of infectious diseases. The fact that autologous stem cell and non-stem cell based therapies do not require an outside donor, makes it more convenient and less infectious. All these factors are boosting the growth of the market in North America. 

Asia Pacific is projected to show the most promising growth in the years to come with high demand from China, Vietnam, Malaysia, and India. The demand is expected to be high as autologous stem cell and non-stem cell based therapies help in the effective treatment of cardiovascular diseases. Sophisticated healthcare infrastructure and favorable tax and reimbursement policies are also expected to aid the growth of the Asia Pacific autologous stem cell and non-stem cell based therapies market. 

Autologous Stem Cell and Non-Stem Cell Based Therapies Market: Companies Mentioned

Some of the leading players operating in the autologous stem cell and non-stem cell based therapies market are Fibrocell Science, Inc., Aastrom Biosciences, Dendreon Corporation, NeoStem, Inc., BrainStorm Cell Therapeutics, Regeneus Ltd., and Genzyme Corporation.   

Fill the form for an exclusive sample of this report @
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4001

About Us    

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Sunday, 2 July 2017

Worldwide Sintering Process Market Analysis, Trends and Forecast by 2016 - 2024

Global Sintering Process Market: Brief Account 

The report offered herewith is a comprehensive study of the global sintering process market, providing a detailed account of drivers and restraints, growth opportunities, geographical segmentation, and competitive landscape that are in the best knowledge of expert research analysts. 

The global sintering process market is marked by innovations and new product developments. High speed sintering (HSS) invented by Neil Hopkinson leading the 3D printing department of Xaar, an inkjet printhead manufacturer, is expected to have a key role to play in the accomplishment of the company’s 2020 vision. Apart from acquisitions and partnerships, Xaar will look to capitalize on the fast growth of 3D printing to double its revenue by 2020. The invasion of HSS in 3D printing is likely to make the process competitive with injection molding and other mass manufacturing technologies. 


Application and end user are predicted to be crucial classifications of the global sintering process market. Participants could count on the various applications and end users of the sintering process to ensure an impressive growth rate. 

Global Sintering Process Market: Trends and Opportunities 

The powder metallurgy sector is anticipated to set the bar for a tangible growth in the world sintering process market. The quality of different physical properties lent by this technique to sintered parts and the processing cost involved are expected to play a significant part in the growth of the world sintering process market. In fact, these are the primary parameters based on which the efficiency of the sintering process is assessed. A variety of sectors such as construction, machine tool and power, automotive, electrical and electronic, defense, and aerospace employ sintered metals at a telling degree. Although non-ferrous and ferrous metals are commonly used in the sintering process, ceramics, cermets, and rare earth intermetallics are also sintered. 

Replaceable technologies could pose some threat to the world sintering process market on account of the harmful effects of the process on the environment and human health. Besides this, there are a multitude of government laws laid down regarding the usage of the process. However, various end-user applications of the sintering process in a wide range of industries owing to technological developments are envisaged to help the world sintering process market dissolve the effect of its deterrents. 

Global Sintering Process Market: Geographical Analysis 

The international sintering process market in Asia Pacific is envisioned to benefit from the stupendous rise of the construction and automotive sectors. Indonesia, China, India, and other developing economies of Asia Pacific could raise the hopes of players operating in the regional sintering process market. Stringent government regulations pertinent to the application of the sintering process are foretold to lead a downward growth trend in Europe and North America. Howbeit, the Asia Pacific sintering process market advantaged with aggressive technological and industrial development could prepare a fertile ground of growth for players to ride on. 

The demand in the international sintering process market is predicted to augment with the need for an effective industrial technique to enhance the capabilities of a diverse range of metals. The analysts foresee the international sintering process market to be solely stimulated by the powder metallurgy sector, although the growth is prognosticated to remain stable over the course of the forecast period. 

Fill the form for an exclusive sample of this report @
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=3954

About Us    

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Friday, 30 June 2017

Worldwide CNV (Choroidal NeoVascularization) Market Analysis, Trends and Forecast by 2015 - 2023

Choroid is the part of eye that lies in between the retina (vision sensory area) and the sclera (the outer layer of the eye), this area consist of blood vessels that supply nutrients to the retinal part of our eye. Choroidal NeoVascularization (CNV) is a disease, which is characterized by the formation of new blood vessels that arise either due to the presence of Vascular Endothelial Growth Factors (VGEF) or due to Age-related Macular Degeneration (AMD). This results in fluid accumulation below the retinal pigment epithelium, which can lead to vision loss or extreme myopic vision among individuals. CNV is also seen in individuals with diabetic retinopathy. In rare cases, it can occur among individuals with defects in Bruch's membrane, the innermost layer of the choroid. It has also been observed by the American Academy of Ophthalmology and other reports that patients with CNV in one eye have a very high probability to contract CNV in the other eye within a short frame of time. According to the British Journal of Ophthalmology published in 2007, age?related macular degeneration (AMD) is one of the leading causes of irreversible sight loss among adults registered as legally blind. Among these, two-thirds of people with AMD have the wet form, which can progress quickly causing irreversible sight loss within days or weeks. In 2007, approximately 250,000 people were suffering from neovascular AMD in the U.K, with an incidence rate of 25,000 and 30,000 new cases annually. 

Obtain Report Details @

The only successful treatment option that is available commercially in the market for CNVs include intravitreal (direct to the eye) injections of anti-VEGF drugs to control the neovascularization and reduce the fluid accumulated. The most common anti-VGEF compounds are Ranibizumab (Trade name: Lucentis), Bevacizumab (Trade name: Avastin) and the novel drug Pegaptanib (Trade name: Macugen). These drugs belong to a class called anti-angiogenic drugs, their primary objective being the inhibition of the growth of new blood vessels. Anti angiogenic drugs are more commonly used for cancer treatment, where cancerous cells promote angiogenesis resulting in the proliferation of cells in large numbers, thus forming tumors. Bevacizumab is a successfully used cost effective drug for the treatment of cancer as well as AMD related CNVs with a very high half life (more than twice) in comparison with Ranibizumab. However chances of adverse effects with Bevacizumab are comparatively higher, hence Ranibizumab (Lucentis) is now currently the most effectively and safely used treatment for CNV. Pegaptanib on the other hand is in Phase IV of the clinical trials wherein only 1000 patients so far have been treated with significant success rate. 

With increasing aging population throughout the world the probability of occurrence of wet-AMD is high, especially in China and Japan where the aging population is predicted to tip over the young adult population. The patents for both Bevacizumab and Ranibizumab are till 2018 hence after patent expiry it is predicted that their sales shall significantly increase, especially with the entrance of Asian drug manufacturers. 

Currently the companies that manufacture Ranibizumab are Novartis (licensed) in global market and Genetech (patented) in the U.S. Bevacizumab too was developed by Roche Pharma in association with Genentech and is currently marketed by Roche internationally. Pegaptanib is manufactured by Eyetch Inc. and marketed by Pfizer Inc. 

Pegaptanib has been approved and is available only in North America, Europe, Brazil and Australia. Ranibizumab is available under the name Lucentis with high market share in Europe and North America and growing in Asia-Pacific region. Bevacizumab is sold as Avastin globally with highest growth rate observed in Asia and highest voluminous growth seen in the North Americas and European markets.  

Fill the form for an exclusive sample of this report @
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=8194

About Us    

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Hypercholesterolemia Market Worldwide Industry Volume By Region 2015 - 2023

Increased level of total cholesterol and LDL (bad) cholesterol in the blood leads to hypercholesterolemia. The normal biological range of total blood cholesterol is 140-200 mg/dL. Hypercholesterolemia leads to cardiovascular diseases such as atherosclerosis, stroke etc. Human blood cholesterol mainly consists of High-density lipoprotein (HDL) cholesterol, Low-density lipoprotein (LDL) cholesterol, Very low-density lipoprotein (VLDL) cholesterol. HDL cholesterol is termed as good cholesterol for the body. High level of HDL cholesterol reduces the risk for heart diseases and HDL naturally removes cholesterol from cells by reverse cholesterol transport to the liver. On the other, hand LDL adds to plaque, a hard and dense deposit that blocks the arteries and make the artery wallless flexible. This type of medical condition is termed as atherosclerosis. Clot forms and blocks the narrowed arteries leads to heart attack, stroke and peripheral artery diseases.


Hypercholesterolemia usually result from the grouping of genetic and environmental risk factors. Genetic disorder leads to heterozygous familial hypercholesterolemia. It happens due to the existence of the mutated copy of the LDLR gene (LDL receptor gene). Individuals with the homozygous gene, containing dual copies of the gene mostly suffer from severe cardiovascular diseases in their childhood and people with the heterozygous gene that is with a solitary copy of the gene suffer from cardiac ailment in their 30s or 40s.

Hypercholesterolemia due to lifestyle selections includes unhealthy eating habits, lack of exercise, and intake of tobacco smoking strongly hampers the quantity of cholesterol in the blood. However, there are few secondary reasons as well such as diabetes mellitus (Type 2), alcohol intake, obesity, monoclonal gammopathy, dialysis and others.

The hypercholesterolemia treatment market is increasing at a substantial rate due to technologically advanced diagnosis, government initiatives, improved reimbursement scenario lifestyle changes, rising awareness about different cardiovascular diseases. Treatment for hypercholesterolemia mainly includes intake of statins and opting for a better lifestyle. Factors such as high cost in the diagnosis, lack of awareness and lack of knowledgeable experts for proper diagnosis of the disease are restricting the global market for hypercholesterolemia treatment. 

North America rules the global market for hypercholesterolemia treatment reason beingincreased incidences of heart diseases and related disorders in the region. Asia, followed by Europe, predicted to witness a high growth rate in coming years in the hypercholesterolemia market. Developing countries like China and India are also growing fast in these markets by the presence of a large patient pool and growing government initiatives. Hypercholesterolemia Market can be segmented as drug class and geography. Drug class can categorize hypercholesterolemia market as statins, niacin, bile-acid resins, fibric acid derivatives, cholesterol absorption inhibitors. 

Some of the key players in this Hypercholesterolemia market AbbVie, Inc., AstraZeneca Plc., Amgen, Inc., Eli Lilly and Company, Merck & Co., Novartis AG and Pfizer, Tekmira Pharmaceuticals Corporation. 

Fill the form for an exclusive sample of this report @
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=8176

About Us    

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Worldwide Bacterial Disease Diagnostic Market By Analysis of Major Industry Segments 2015 - 2023

Bacteria are of various types some of them are infectious whereas, majority of them are beneficial for the body. Any bacteria that cause an infectious disease are called pathogens. Diagnosis of causative organism of a bacterial disease has always been difficult, since infections show similar symptoms like fever and lethargy. Routine clinical diagnosis have high error rate, administering the wrong antibiotics can sometimes increase infection and can even result in death. The oldest method for diagnosis has been culturing of bacteria, these cultures allow only specific species to grow in the medium, however this method is very time consuming and can seldom be done on time to successfully diagnose and treat the patient. Newer techniques like rapid culture methods with ionized mass spectrometry are currently in use for diagnosing some rare bacteria.


Currently, PCR (Polymerase Chain Reaction) sequencer is the most favored and well know method. The PCR can amplify bacterial DNA a thousand times if necessary, any routine diagnosis requires only a min of 10 – 80 bacteria, which means PCR has a very high sensitivity. This factor is exploited for countless diagnostic processes. PCR also doesn’t require purification of the bacterial sample compared to older methods as it has specific sequences to identify bacterial DNA. Versatility of PCR has proven to be a big advantage, diagnosis of many dangerous diseases like tuberculosis, pneumonia etc are done with the intention to specify whether the strain is drug resistant. This greatly increases the success rate of treatment. The shortcomings of PCR are also eminent; PCR is susceptible to false positive report in presence of any contamination, it is also not useful in calculating the success of a treatment, as PCR recognizes dead and living cells as the same. Technical expertise is a major requirement in PCR handling. PCR techniques also require a number of biochemical reagents that are quite expensive. Development has been made to create more specific and customized versions of PCR machines with greater accuracy and low false positive rates. These include; PCR ribotyping techniques which are much faster and highly specific to certain strains; multiplex PCR that can detect multiple pathogens in a single go and nested PCR a modified error negating version of PCR. Such modified versions are currently available in laboratories and are offered as a diagnostic service and are seldom used as a large-scale diagnostic tool. However, with the entry of novel ‘portable PCR’ there is a scope for diagnostic evolution in future.

On the other hand, scientists throughout the world are developing ideas in Electrophoresis methods and tests for biological proteins that are produced in the body in reaction to an infection. In newborns such tests are done to investigate the diseases that have late onset period. With increasing population and globalization, the chance of infection remains high, diseases too have gone global. In addition, diagnosing a disease before it becomes an epidemic is very critical. Thus, PCR and electrophoresis machines helps in early and fast diagnosis of these diseases that leads to an increase in the demand for PCR and electrophoresis machines. However, lack of skilled professionals/technicians and high cost of these devices restricts the overall growth of bacterial disease diagnostics market.

Some of the companies that produce PCR machines are Techne, GeneriBiotech, Roche diagnostics and ZyGEM to name a few. The sales of these devices are currently highest in the developed nations of the North Americas and Europe whereas, Asia-Pacific region shows the highest growth followed by South America and Africa.

Fill the form for an exclusive sample of this report @
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=7823

About Us    

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.